跳至主要内容
临床试验/ACTRN12609000939291
ACTRN12609000939291已完成3 期

In patients undergoing colonic EMR (endoscopic mucosal resection) for large sessile polyps, succinylated gelatin may be a superior submucosal injectant compared with normal saline.

Dr Alan Moss and Dr Michael Bourke0 个研究点目标入组 160 人开始时间: 2009年11月3日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Sessile polyp sized 20mm or larger intended for EMR

排除标准

  • - Personal history of allergy to gelatin, Gelofusine or Haemaccel
  • - Pregnancy: currently pregnant or attempting to become pregnant
  • - Lactation: currently breastfeeding
  • - Taken clopidogrel within 7 days
  • - Taken warfarin within 5 days
  • - Had full therapeutic dose unfractionated heparin within 6 hours
  • - Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours
  • - Known clotting disorder

研究者

发起方
Dr Alan Moss and Dr Michael Bourke

相似试验